Pharmaceutical Nanotechnology and Nanomedicine

Biography

Prof Istvan Toth PhD, DSc ARC Australia Professorial Fellow is a chemical engineer and an internationally recognized expert in drug delivery. His major research interests are immunoadjuvants, carbohydrates, lipids, peptides, nucleosides and nucleotides. At the School of Pharmacy, University of London and at the University of Queensland prof Toth built up a strong, very productive research group where the research orientation well suited the direction of modern multidisciplinary pharmaceutical sciences. All his former PhD students have excellent reputable jobs both at Academia and at Pharmaceutical Industry. He has refereeing duties for many international scientific journals and for scientific granting bodies. He has also demonstrated track record in research commercialization he is a one of key founders of Alchemia (ASX listed), Implicit Bioscience Pty Ltd, Neurotide Pty Ltd and TetraQ. Prof Toth is also a Scientific Advisory Board Member of Implicit Bioscience Pty Ltd. Brisbane, Australia and Proxima Concept Ltd, London, UK. He has obtained a Business/Higher Education Round Table (BHERT) Award: Outstanding Achievement in International Collaborative R&D. Toth has more than 300 peer-reviewed publications and 43 patents. He is the Editor in Chief of Current Drug Delivery; Drug Delivery Letters, Associate Editor of Medicinal Chemistry; Board Member of Mini Reviews in Medicinal Chemistry, Open Drug Delivery, Open Medicinal Chemistry and Current Patents in Drug Delivery; Prof Toth has been appointed as a member of the ARC College of Experts (2008-2010) and has been the funding President of the Australian Chapter of Controlled Release Society. He is a Fellow of the Royal Australian Chemical Institute (FRACI) and the Queensland Academy of Science and Art (FQA).

Research Interest

expert in drug delivery major research interests are immunoadjuvants, carbohydrates, lipids, peptides, nucleosides and nucleotides